|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Suda K, Tomizawa K, Yatabe Y and Mitsudomi
T: Lung cancers unrelated to smoking: Characterized by single
oncogene addiction? Int J Clin Oncol. 16:294–305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takeuchi K, Soda M, Togashi Y, Suzuki R,
Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et
al: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Falchook GS, Ordóñez NG, Bastida CC,
Stephens PJ, Miller VA, Gaido L, Jackson T and Karp DD: Effect of
the RET inhibitor vandetanib in a patient with RET fusion-positive
metastatic non-Small-cell Lung cancer. J Clin Oncol. 34:e141–e144.
2016. View Article : Google Scholar
|
|
10
|
Shaw AT, Ou SH, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 371:1963–1971. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li T, Kung HJ, Mack PC and Gandara DR:
Genotyping and genomic profiling of non-small-cell lung cancer:
Implications for current and future therapies. J Clin Oncol.
31:1039–1049. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papadopoulou E, Tsoulos N, Tsirigoti A,
Apessos A, Agiannitopoulos K, Metaxa-Mariatou V, Zarogoulidis K,
Zarogoulidis P, Kasarakis D, Kakolyris S, et al: Determination of
EGFR and KRAS mutational status in Greek non-small-cell lung cancer
patients. Oncol Lett. 10:2176–2184. 2015.PubMed/NCBI
|
|
13
|
Takeda M, Sakai K, Terashima M, Kaneda H,
Hayashi H, Tanaka K, Okamoto K, Takahama T, Yoshida T, Iwasa T, et
al: Clinical application of amplicon-based next-generation
sequencing to therapeutic decision making in lung cancer. Ann
Oncol. 26:2477–2482. 2015.PubMed/NCBI
|
|
14
|
Shao D, Lin Y, Liu J, Wan L, Liu Z, Cheng
S, Fei L, Deng R, Wang J, Chen X, et al: A targeted next-generation
sequencing method for identifying clinically relevant mutation
profiles in lung adenocarcinoma. Sci Rep. 6:223382016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilkerson MD, Cabanski CR, Sun W, Hoadley
KA, Walter V, Mose LE, Troester MA, Hammerman PS, Parker JS, Perou
CM, et al: Integrated RNA and DNA sequencing improves mutation
detection in low purity tumors. Nucleic Acids Res. 42:e1072014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akagi K, Sakai H, Sudo J, Hommura Y,
Kurimoto F, Komagata H, Akiyama H and Yoneda S: Simple method to
detect important epidermal growth factor receptor gene mutations
with bronchoscopic specimens of lung cancer patients for gefitinib
treatment. Target Oncol. 2:145–151. 2007. View Article : Google Scholar
|
|
17
|
Higasa K, Miyake N, Yoshimura J, Okamura
K, Niihori T, Saitsu H, Doi K, Shimizu M, Nakabayashi K, Aoki Y, et
al: Human genetic variation database, a reference database of
genetic variations in the Japanese population. J Hum Genet.
61:547–553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagasaki M, Yasuda J, Katsuoka F, Nariai
N, Kojima K, Kawai Y, Yamaguchi-Kabata Y, Yokozawa J, Danjoh I,
Saito S, et al ToMMo Japanese Reference Panel Project: Rare variant
discovery by deep whole-genome sequencing of 1,070 Japanese
individuals. Nat Commun. 6:80182015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
21
|
Baek JH, Sun JM, Min YJ, Cho EK, Cho BC,
Kim JH, Ahn MJ and Park K: Efficacy of EGFR tyrosine kinase
inhibitors in patients with EGFR-mutated non-small cell lung cancer
except both exon 19 deletion and exon 21 L858R: A retrospective
analysis in Korea. Lung Cancer. 87:148–154. 2015. View Article : Google Scholar
|
|
22
|
Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH,
Yu CJ, Tsai MF, Shih JY and Yang PC: Good response to gefitinib in
lung adeno-carcinoma of complex epidermal growth factor receptor
(EGFR) mutations with the classical mutation pattern. Oncologist.
13:1276–1284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang TY, Tsai CR, Chen KC, Hsu KH, Lee HM
and Chang GC: Good response to gefitinib in a lung adenocarcinoma
harboring a heterozygous complex mutation of L833V and H835L in
epidermal growth factor receptor gene. J Clin Oncol. 29:e468–e469.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Costa DB, Schumer ST, Tenen DG and
Kobayashi S: Differential responses to erlotinib in epidermal
growth factor receptor (EGFR)-mutated lung cancers with acquired
resistance to gefitinib carrying the L747S or T790M secondary
mutations. J Clin Oncol. 26:1182–1184; author reply 1184-1186.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suzuki A, Mimaki S, Yamane Y, Kawase A,
Matsushima K, Suzuki M, Goto K, Sugano S, Esumi H, Suzuki Y, et al:
Identification and characterization of cancer mutations in Japanese
lung adenocarcinoma without sequencing of normal tissue
counterparts. PLoS One. 8:e734842013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jänne PA, Shaw AT, Pereira JR, Jeannin G,
Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V,
Smith P, et al: Selumetinib plus docetaxel for KRAS-mutant advanced
non-small-cell lung cancer: A randomised, multicentre,
placebo-controlled, phase 2 study. Lancet Oncol. 14:38–47. 2013.
View Article : Google Scholar
|
|
28
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
'uncommon' epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Klughammer B, Brugger W, Cappuzzo F,
Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin
AY, et al: Examining treatment outcomes with erlotinib in patients
with advanced non-small cell lung cancer whose tumors harbor
uncommon EGFR mutations. J Thorac Oncol. 11:545–555. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bean J, Riely GJ, Balak M, Marks JL,
Ladanyi M, Miller VA and Pao W: Acquired resistance to epidermal
growth factor receptor kinase inhibitors associated with a novel
T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Clin Cancer Res. 14:7519–7525. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chmielecki J, Foo J, Oxnard GR, Hutchinson
K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, et al:
Optimization of dosing for EGFR-mutant non-small cell lung cancer
with evolutionary cancer modeling. Sci Transl Med. 3:90ra592011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hata AN, Niederst MJ, Archibald HL,
Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang
HE, Krishnamurthy Radhakrishna V, et al: Tumor cells can follow
distinct evolutionary paths to become resistant to epidermal growth
factor receptor inhibition. Nat Med. 22:262–269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thress KS, Paweletz CP, Felip E, Cho BC,
Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et
al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nat Med.
21:560–562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kempf E, Rousseau B, Besse B and Paz-Ares
L: KRAS oncogene in lung cancer: Focus on molecularly driven
clinical trials. Eur Respir Rev. 25:71–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ostrem JM, Peters U, Sos ML, Wells JA and
Shokat KM: K-Ras(G12C) inhibitors allosterically control GTP
affinity and effector interactions. Nature. 503:548–551. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hames ML, Chen H, Iams W, Aston J, Lovly
CM and Horn L: Correlation between KRAS mutation status and
response to chemotherapy in patients with advanced non-small cell
lung cancer. Lung Cancer. 92:29–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Suda K, Mizuuchi H, Murakami I, Uramoto H,
Tanaka F, Sato K, Takemoto T, Iwasaki T, Sekido Y, Yatabe Y, et al:
CRKL amplification is rare as a mechanism for acquired resistance
to kinase inhibitors in lung cancers with epidermal growth factor
receptor mutation. Lung Cancer. 85:147–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim GW, Song JS, Choi CM, Rho JK, Kim SY,
Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, et al: Multiple
resistant factors in lung cancer with primary resistance to EGFR-TK
inhibitors confer poor survival. Lung Cancer. 88:139–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Clinical Lung Cancer Genome Project
(CLCGP); Network Genomic Medicine (NGM): A genomics-based
classification of human lung tumors. Sci Transl Med.
5:209ra1532013.PubMed/NCBI
|
|
41
|
Barlesi F, Mazieres J, Merlio JP,
Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I,
Westeel V, et al Biomarkers France contributors: Routine molecular
profiling of patients with advanced non-small-cell lung cancer:
Results of a 1-year nationwide programme of the French Cooperative
Thoracic Intergroup (IFCT). Lancet. 387:1415–1426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Colwell J: NCI-MATCH trial draws strong
interest. Cancer Discov. 6:3342016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dacic S, Villaruz LC, Abberbock S,
Mahaffey A, Incharoen P and Nikiforova MN: ALK FISH patterns and
the detection of ALK fusions by next generation sequencing in lung
adenocarcinoma. Oncotarget. 7:82943–82952. 2016.PubMed/NCBI
|
|
44
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al
AURA3 Investigators: Osimertinib or platinum-pemetrexed in EGFR
T790M-positive lung cancer. N Engl J Med. December 6–2016.Epub
ahead of print. PubMed/NCBI
|
|
45
|
Paweletz CP, Sacher AG, Raymond CK, Alden
RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English
JM, et al: Bias-corrected targeted next-generation sequencing for
rapid, multiplexed detection of actionable alterations in cell-free
DNA from advanced lung cancer patients. Clin Cancer Res.
22:915–922. 2016. View Article : Google Scholar :
|
